Murat Bardakci, Hilal Karakas, Dogan Bayram, Nilufer Avci, Sait Kitapli, Mirac Ozen, Ferit Aslan, Caglar Koseoglu, Ahmet Kadioglu, Ilknur D Onur, Teoman Sakalar, Mahmut Buyuksimsek, Ali Alkan, Yakup Ergun, Ali O Kaya, Burak Bilgin, Bulent Yalcin
While some clinics have adopted abbreviated neoadjuvant treatment for HER2-positive breast cancer, there remains a shortage of comprehensive clinical data to support this practice. This is a retrospective, multicenter study. A total of 142 patients were included in the study who are HER2-positive breast cancer, aged ≤ 65 years, with left ventricular ejection fraction ≥ 50%, received neoadjuvant chemotherapy and underwent surgery at 10 different oncology centers in Türkiye between October 2016 and December 2022...
May 9, 2024: Scientific Reports